EMA Recommends EU-Wide Desloratadine Switch
Executive Summary
Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.
You may also be interested in...
Longer Exclusivity Periods For EU Centralized Rx-To-OTC Switches? Commission Says No
One way to revitalize interest in the EU's centralized switch procedure would be to introduce longer data exclusivity periods or market exclusivity for successful applicants, concluded an AESGP expert switch panel presenting at the association's 59th Annual Meeting in Paris, France. However, a European Commission representative told another panel that this was not under consideration as part of the EU pharmaceutical legislation revision.
Cipla Switches Fexofenadine For Hives From Rx-To-OTC Status In The UK
UK hives sufferers can now buy a specific OTC medicine for their condition thanks to a successful Rx-to-OTC switch from Cipla.
Recordati Launches Fortacin OTC In Germany Following EU-Wide Switch
Men in Germany can now purchase premature ejaculation treatment Fortacin without a prescription as a result of the EU-wide switch of the drug earlier this year.